EGFR and non-small cell lung carcinoma: The 5-year survival rate of patients with EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs is 14.6%.[2] Patients with advanced NSCLC with long-term survival (>10 years) are still rare.